Money
Briefing: DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing
Strategic angle: DAFNA Capital has made adjustments to its holdings in the iShares Biotechnology ETF as part of a broader strategy in the biotech sector.
editorial-staff
1 min read
Updated 21 days ago
On March 21, 2026, DAFNA Capital filed with the SEC, detailing modifications to its holdings in the iShares Biotechnology ETF.
These adjustments are part of a larger strategy aimed at optimizing their biotech portfolio.
The iShares Biotechnology ETF continues to play a significant role in DAFNA's investment framework, despite the recent changes.